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1. Introduction 
Osteopontin (OPN), a cytokine like ECM associated member of Small Integrin Binding 
LIgand N-linked Glycoprotein (SIBLING) family of protein plays an important role in 
determining the metastatic potential of many cancers. The function of OPN in various 
pathophysiological conditions, especially in cancer indicated that the variation in post-
translational modification generate different functional forms that might alter its normal 
physiological functions. Recent data indicated that OPN regulates tumor growth through 
induction of pro-angiogenic and metastatic genes like COX-2, and VEGF expressions and 
activation of matrix metalloproteinase (MMP) in cancer cells. The exact role of stroma- and 
tumor-derived OPN in regulation of tumor growth and angiogenesis in various cancers is 
not well understood. Therefore, it is important to delineate the mechanism by which both 
tumor and stroma-derived OPN control the cell migration and tumor growth. p70S6 kinase, 
STAT3 and VEGF are directly involved in regulation of breast tumor growth and 
angiogenesis. But, the mechanism by which OPN regulates p70S6 kinase and STAT3 
activation and VEGF expression leading to breast cancer cell migration, tumor growth and 
angiogenesis are not well defined. We have recently shown that OPN induces p70S6 kinase 
phosphorylation in a site specific manner. Interestingly, OPN has no effect on mTOR 
phosphorylation, but overexpression of mTOR does not regulate OPN-induced 
phosphorylation of p70S6 kinase. Overexpression of mTOR/p70S6 kinase suppresses OPN-
induced ICAM-1 expression, while treatment with rapamycin enhances OPN-induced 
ICAM-1 expression. Our recent data also indicated that OPN upregulates JAK2 dependent 
STAT3 activation in breast cancer cells. Wild type STAT3 enhanced whereas mutant STAT3 
suppressed OPN-induced breast tumor cell migration. Cells overexpressing STAT3 
upregulate whereas mutant STAT3 downregulate OPN-induced tumor growth leading to 
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Bcl2 and cyclin D1 expressions. Our data also revealed that OPN augments breast cancer cell 
migration, angiogenesis and tumor growth through induction of VEGF expression. Thus, 
targeting OPN and its regulated signalling cascade may develop an effective therapeutic 
approach for the management of breast cancer. 
2. General features of breast cancer 
The critical features that define cancer encompass the six core hallmarks of the disease as 
described recently (Hanahan and Weinberg, 2011). These hallmarks are sustained 
proliferative signalling, evading growth suppressors, activating invasion and metastasis, 
overcoming replicative senescence, inducing angiogenesis and resisting cell death (Hanahan 
and Weinberg, 2000). Breast cancer represents malignant transformation of the epithelial 
cells lining the ducts or lobules of the breast, occurring as a result of unrestricted cellular 
proliferation possibly owing to accumulation of a series of somatic or germ line mutations. 
Majority of the breast cancer is a result of somatic or acquired mutations and it is the most 
common form of cancer affecting women worldwide. Benign breast tumors are treatable and 
hence not a grave threat in contrast to malignant breast cancer where many complex 
processes are involved that are difficult to target. Invasion, angiogenesis and metastasis are 
the defining attributes of malignancy and occur as early events in cancer progression. 
Mutations in certain genes lead to sporadic cases of breast cancer. Tumor suppressor genes 
like p53 control unrestricted proliferation of cells. It is noteworthy to mention about two 
related genes such as p63 and p73 which are yet to assume importance as candidates for 
alternative regimens for the treatment of cancer. These are reported to be involved in 
embryonic development and their roles in attenuating cancer progression are under study. 
Boominathan has provided mechanistic insights into how p53, p63, and p73 regulate the 
components of the miRNA processing and how p53, TA-p63, and TA-p73 regulated 
miRNAs inhibit tumorigenesis, EMT, metastasis, and cancer stem cell proliferation 
(Boominathan, 2010). The first clinical trials of attempting to use p73 to combat a hard-to-
treat-type of breast cancer have been initiated (Leslie, 2011).  
The other two breast cancer specific tumor suppressor genes, BRCA1 and BRCA2 protect the 
cells from dysregulation leading to unrestrained cellular proliferation (Stefansson et al, 
2009). A member of EGF receptor superfamily called erbB2 or HER2/neu is a receptor for 
human epidermal growth factor that is present on the breast cancer cells and stimulates the 
cells to grow and divide. Overexpression of HER2/neu due to gene amplification is 
associated with transformation of human breast epithelium. Apart from mutations in tumor 
suppressor genes and oncogenes, breast cancer is also associated with the presence of ER 
and PR. Breast cancers are sub-divided into four groups based on IHC profile of ER/PR and 
Her2/neu expression: luminal A (ER and/or PR +ve, HER2 –ve), luminal B (ER and/or PR 
+ve, HER2 +ve), HER2 positive (ER and PR -ve, HER2 +ve) and triple negative (all –ve). 
These classifications of breast cancers are based on which hormone fuels their growth and 
helps decide the course of hormone targeted therapy. Triple negative breast cancer is 
marked by the absence of hormone receptors and HER2/neu and forms belligerent tumors 
that are unresponsive to hormonal therapies (tamoxifene, aromatase inhibitors) or HER2 
directed therapies (herceptin, lapatinib) ( Chen and Russo, 2009). Staging of breast cancer is 
performed by employing the widely accepted TNM classification which describes the 
individual stages of the tumor, node and metastases (TNM) of the cancer. The tumor grade 
of invasive carcinomas is classified according to the Scarff–Bloom–Richardson (SBR) system. 
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Clinical studies have revealed that higher expression of OPN is found in tumor tissue and 
serum of breast cancers (Shevde et al, 2006). Enhanced expression of OPN can be correlated 
with increase in tumor growth and metastasis, suggesting that OPN can be used as a 
diagnostic and prognostic biomarker for breast cancer. Earlier micro array analysis data 
revealed that expression of OPN is upregulated in metastatic breast cancers (Cook, 2005). 
OPN is an extracellular matrix (ECM)-associated, SIBLING family of cytokine-like, 
noncollagenous, sialic acid rich phosphoglycoprotein (Rangaswami, et al 2006). OPN 
controls normal physiological and various pathophysiological processes such as myocardial 
necrosis, restenosis, atherosclerosis and autoimmune diseases (Panda et al, 1997). OPN acts 
as an important oncogenic molecule which is involved in all the stages of cancer progression 
including tumor invasion, angiogenesis and metastasis. Previous reports have indicated that 
OPN is also overexpressed in tumor-educated stromal cells suggesting its involvement in 
the crosstalk between tumor and stromal compartment that ultimately leads to cancer 
progression (Osterreicher, 2011). Earlier results indicate that OPN could regulate the 
expression of several oncogenic and angiogenic molecules through activation of various 
signalling mechanism (Chakraborty et al, 2006).  
3. Structure, functions and mediators of osteopontin 
Osteopontin was initially characterized in 1979 as a phosphoprotein secreted by 
transformed malignant epithelial cells and has since been under extensive study. The 
human OPN gene sprawls across 8 kilobases and is localized at chromosome 4q13 in human 
as a single copy gene with seven exons and six introns (Wai and Kuo, 2004). Alternative 
splicing yields three distinct splice variants- OPN-A, the full-length transcript, OPN-B, 
lacking exon 5 and OPN-C lacking exon 4 ( He et al, 2006). Two isoforms of OPN, a full-
length secreted OPN (Opn-s) and an intracellular OPN (Opn-i) are generated from 
alternative translation of a non-AUG site downstream of the canonical AUG sequence 
(Shinohara et al, 2008). These two isoforms occupy characteristic intracellular sites and 
mediate distinct functions in dendritic and T cells (Shinohara et al, 2008).  
A full length human OPN consists of about 314 amino acid residues with a molecular 
weight in the range of 44-75 kDa, resulting from the varying degree of posttranslational 
modifications. Within the functional domains of OPN, there are specific motifs essential for 
the binding of OPN to its cell surface receptors, integrins and CD44 for mediating its 
biological activities (Figure 1). Whereas the N-terminal fragment contains the RGD motif, 
the SVVYGLR motif, a thrombin cleavage site and an aspartic acid rich site, the C-terminal 
fragment contains a calcium-binding site and CD44 binding site. The RGD motif necessary 
for the attachment of integrins such as v3, v5, v1 and 51 is embedded within exon 
6. A central thrombin cleavage site distal to the RGD motif divides OPN into two similar-
sized fragments. The SVVYGLR motif binds to integrins, 91 and 41 and the aspartic 
acid rich site binds hydroxyapatite in bones. The CD44 interacts through the C-terminal of 
OPN. OPN is involved in maintaining calcium homeostasis via its calcium binding site. 
OPN upon binding with integrins or CD44 regulates breast cancer cell proliferation, 
migration, invasion and chemotaxis. OPN plays an important role in regulation of tumor 
progression, angiogenesis and metastasis in breast cancer. OPN is detected in many 
biological fluids like plasma of metastatic breast cancer patients, urine, milk and seminal 
fluids. The ligation of OPN to its receptors stimulates a cascade of signalling pathways 
which cross talk and foster neoplastic growth in breast cancer (Rangaswami et al, 2006). 
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Fig. 1. Schematic representation of the domain structure of OPN. The N-terminal fragment 
contains a poly D rich region, calcium binding site, RGD motif and SVVYGLR. Various 
integrins interact with the N-terminal domain of OPN while C-terminal domain of it 
interacts with CD44, v3-6. 
4. Pleiotropic function of OPN in breast cancer 
Breast cancer progression depends on an accumulation of metastasis supporting cell 
signaling molecules that target various signal transduction pathways. These complex 
signaling mechanisms can result in changes in gene expression, which ultimately lead to 
alterations in cellular properties involved in malignancy such as adhesion, migration, 
invasion, enhanced tumor cell survival, angiogenesis and metastasis (Figure 2). Increased 
expressions of OPN and its receptors, integrins and CD44 correlate with enhanced breast 
tumor epithelial cell migration, tumor progression and metastasis. Among all splice variants 
of OPN, OPN-C is a highly specific marker for transformed breast cancer cells (He et al, 
2005). Rittling et al have reported that OPN associated with tumors is primarily soluble, and 
that OPN can neither support endothelial cell proliferation nor prevent apoptosis of these 
cells in the absence of adhesion (Rittling et al, 2002).  
OPN activates v3 integrin-mediated PI 3'-kinase/IKK-dependent NF-B activation and 
uPA secretion leading to breast cancer cell migration (Das et al, 2003). Previous reports have 
shown that OPN induces v3 integrin-mediated AP-1 activation and uPA secretion 
through c-Src/EGFR/ERK signaling pathways and all of these ultimately control breast 
cancer cell migration (Das et al, 2004). Recent studies suggest that mutant OPN lacking 
thrombin cleavable domain decreases cell adhesion and primary tumor latency time, and 
increases uPA expression, primary tumor growth and lymph node metastatic burden in 
MDA-MB-468 breast cancer cells (Beausoleil et al, 2011). Cook et al have shown that 
hyaluronan synthase 2 (HAS2) is found to be upregulated by OPN in breast cancer cells 
(Cook et al, 2006). It is reported that OPN induces NF-κB activation and NF-κB dependent 
AP1-mediated ICAM-1 expression through mTOR/p70S6 kinase pathways in breast cancer 
cells. The study suggests that inhibition of mTOR by rapamycin induces whereas 
overexpression of mTOR/p70S6 kinase suppresses OPN-induced ICAM-1 expression. Thus 
OPN stimulates p70S6 kinase phosphorylation at Thr-421/Ser-424, but not at Thr-389 or Ser-
371 and mTOR phosphorylation at Ser-2448. Overexpression of mTOR has no effect in 
regulation of OPN-induced phosphorylation of p70S6 kinase at Thr-421/Ser-424 (Ahmed 
and Kundu, 2010). Recent reports also suggested that OPN induces ǂvǃ3 integrin-mediated 
JAK2 dependent STAT3 activation in breast cancer cells. OPN protects the cells from 
staurosporine (STS)-induced apoptosis through JAK2/STAT3 pathway. Wt STAT3 in  
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Fig. 2. Model depicting various signalling pathways involved in breast cancer cells. These 
pathways include estradiol, VEGF, TGF beta and EGF-induced signalling that promote cell 
growth, angiogenesis and prevention of cell death. 
presence of OPN induces breast tumor progression through up regulation of Bcl2 and cyclin 
D1 expression in breast cancer cells (Behera et al, 2010). It has been also reported that both 
exogenous and tumor-derived OPN triggers vascular endothelial growth factor (VEGF)–
dependent tumor progression and angiogenesis by activating breast tumor kinase (Brk)/NF-
κB)/ATF-4 signaling cascades through autocrine and paracrine mechanisms in breast cancer 
models (Chakraborty et al, 2008). Curcumin inhibits OPN-induced VEGF expression leading 
to suppression of tumor angiogenesis in breast cancer (Chakraborty et al, 2008). Mi et al have 
demonstrated that OPN promotes CCL5-mesenchymal stromal cell (MSC) mediated breast 
cancer metastasis. They have shown that tumor derived OPN induces MSC expression of 
CCL5 through integrin mediated AP1 transactivation and further demonstrated that 
concomitant inoculation of MSC with MDA-MB-231 induces tumor growth and metastasis. 
These results suggested that tumor derived OPN promotes tumor progression through 
transformation of MSC into Cancer associated fibroblast (CAF) (Mi et al, 2011).  
5. OPN as a chemoattractant cytokine and pro-angiogenic factor 
OPN mediates RGD dependent chemotaxis, attachment and migration in many epithelial 
cell types (Celetti et al, 2005). It aids preferential metastasis of breast cancer cells to bone 
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(Kang et al, 2003). OPN functions in cell adhesion, chemotaxis, macrophage-directed 
interleukin-10 (IL-10) suppression, stress-dependent angiogenesis, prevention of apoptosis, 
and anchorage-independent growth of tumor cells by regulating cell-matrix interactions and 
cellular signaling through binding with integrin and CD44 receptors (Wai et al, 2004). 
Correlative evidence has shown that the v3 integrin receptor appears to be preferentially 
used by more malignant breast epithelial cell lines in binding and migrating toward OPN 
(Tuck et al, 2000). Cancer metastasis involves invasion by the cancer cells, angiogenesis, 
circulation of cancer cells, colonization at a distant site and finally evasion of the host 
immune response. Motility of the cancer cells and degradation of extracellular matrix are 
essential for invasion. Cells cross the basement membrane and move to secondary organ 
sites. This phenomenon occurs due to the secretion of chemokines. Extracellular matrix 
degradation, by both tumor and host cells occurs by the secretion of proteases (Wong et al, 
1998). On the molecular level, the metastatic phenotype is generated by the deregulation of 
cell surface receptors, their ligands, their downstream signaling molecules and extracellular 
matrix proteases. Unlike oncogenes, the genes involved in metastasis are not mutated but 
their expression is deregulated. OPN overexpression or exogenous addition in breast cancer 
cell lines increases the invasiveness of the cells and uPA expression through cell surface 
interactions between integrin and uPA/uPAR. Constitutive activation of NF-B has been 
detected in lymphomas, melanomas and breast cancers and has been shown to correlate 
with oncogenesis.  
A large number of proangiogenic factors and their cognate receptors have been identified 
including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), 
platelet-derived growth factor (PDGF), angiopoietin-1, transforming growth factor beta-1 
(TGF-1), transforming growth factor alpha (TGF-), and epidermal growth factor (EGF) 
( Liotta et al, 2001). VEGF is one of the best characterized pro-angiogenic factors among 
other growth factors in terms of its specificity for the vascular endothelium (Mcmahon, 
2000). OPN is involved in angiogenesis through v3 integrin-mediated upregulation of 
VEGF expression. It can stimulate adhesion and migration of endothelial cells. Therefore, 
OPN and v3 integrin play significant roles in vascular repair and regeneration. It has been 
reported that OPN protects the endothelial cells from apoptosis. This interaction is mediated 
by v3 integrin and NF-B dependent pathway.  
6. Osteopontin regulates various signaling pathways in breast cancer 
6.1 OPN controls tumor angiogenesis through VEGF/VEGFR signaling pathway  
The molecular mechanism of OPN-induced VEGF expression and its potential role in 
regulating in vitro cell motility which ultimately controls in vivo tumor growth and 
angiogenesis in breast cancer model was described earlier (Chakraborty et al, 2008). The 
study highlighted the role of OPN in induction of neovascularization by enhancing VEGF 
expression through activation of breast tumor kinase (Brk)/NF-B/ATF-4 pathways (Figure 
3). OPN was shown to trigger VEGF-dependent tumor progression and angiogenesis by 
activating Brk/NF-κB/ATF-4 signaling cascades through autocrine and paracrine 
mechanisms in breast cancer cells. VEGF promoter activity and its expression in human 
breast carcinoma cell lines was found to be regulated by OPN. OPN induces Brk/NIK-
dependent NF-B-mediated ATF-4 activation that leads to VEGF expression. The study 
revealed that OPN-induced VEGF binds with neuropilin-1 (NRP-1) and enhances VEGF–
NRP-1-dependent tumor cell migration through autocrine pathway. Moreover, OPN 
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induces VEGF dependent KDR phosphorylation leading to increased endothelial cell 
migration and angiogenesis in a paracrine manner. Tumor-endothelial cell interaction 
through binding with NRP-1 and KDR in endothelial cells was observed to be regulated by 
tumor derived VEGF in response to OPN in a juxtacrine manner. Blocking tumor-derived 
VEGF or silencing tumor-derived OPN and NRP-1 significantly suppressed breast tumor 
progression and angiogenesis in nude mice model. Clinical specimen analysis of solid 
human breast tumors exhibited strong correlation between the OPN and VEGF expression 
with different pathologic grades of tumors. Previous reports have also shown that VEGF 
induces mRNA encoding OPN in endothelial cells (Sengar et al, 1996). OPN plays a crucial 
role in determining spontaneous metastatic performance of orthotopic human breast cancer 
xenografts. Changes in levels of OPN induced by silencing with its shRNA or upregulation 
by cDNA altered the ability of breast cancer cells to colonize to distant organs. It has been 
shown that silencing of OPN resulted in reduction of in vivo tumorigenicity through down 
regulation of molecules like uPA, MMP-2 and -9. OPN knocked out mice showed slower 
progression of tumor growth in breast cancer model as compared to wild type mice 
(Chakraborty et al, 2008).  
6.2 OPN inhibits staurosporine (STS)-induced apoptosis through JAK2/STAT3 
signaling pathway 
Earlier reports have indicated that enhanced expression of STAT3 correlates with increased 
tumor growth and poor survival in breast cancer (Garcia et al, 1997). Behera et al have 
recently demonstrated that OPN induces v3 integrin-mediated JAK2 dependent STAT3 
activation in breast cancer cells (Behera et al, 2010). The mechanism by which OPN controls 
JAK2/STAT3 signaling pathway and regulates apoptosis and breast tumor growth was 
studied. OPN was found to activate STAT3 by inducing its phosphorylation through v3 
integrin mediated pathway. OPN has been observed to regulate STAT3 nuclear 
translocation through v3 integrin mediated and JAK2 dependent pathway. It was further 
established that OPN, through promoting STAT3-DNA binding ultimately regulates the 
expression of downstream molecules such as cyclin D1 and Bcl2 and thus influences 
survival and cell migration in breast cancer (Figure 3). Cells transfected with wt STAT3 
showed enhanced cell migration as well as anti-apoptotic function in response to OPN, as 
opposed to cells transfected with the mutant forms of STAT3. The study revealed that OPN 
protects the cells from staurosporine (STS)-induced apoptosis through JAK2/STAT3 
pathway. Cells stably transfected with wt STAT3 and not with mutant STAT3 were 
observed to enhance tumor growth in response to OPN in mice models. Enhanced 
expressions of Bcl2 and cyclin D1 in STAT3- overexpressed tumors in response to OPN were 
indicative of the significance of STAT3 in OPN-induced Bcl2 and cyclin D1 expression and 
tumor progression. Clinical specimen analysis revealed an enhanced expression of OPN and 
phosphorylated STAT3 and their correlation with higher grades of breast cancer as 
compared to the peripheral normal and lower grades.  
6.3 OPN regulates breast cancer cell motility through mTOR/p70S6 kinase pathway 
mTOR, a serine threonine kinase regulates both cell growth and cell cycle progression 
(Ahmed and Kundu, 2010). mTOR initiates translation by activating the p70S6 kinase. 
Inhibition of mTOR by rapamycin attenuates its ability to control cell cycle progression, 
cell growth and proliferation in normal and malignant cells. They have recently reported 
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that OPN regulates p70S6 kinase and mTOR phosphorylation in breast cancer cells 
(Ahmed and Kundu, 2010). The results revealed that OPN controls NF-κB mediated 
ICAM-1 expression in these cells. The data also showed that OPN induced NF-κB controls 
AP-1 transactivation indicating a cross talk between NF-κB and AP-1 which in turn 
regulates ICAM-1 expression in these cells (Figure 3). The study suggested that inhibition 
of mTOR by rapamycin enhanced whereas overexpression of mTOR/p70S6 kinase 
inhibited OPN-induced ICAM-1 expression. OPN-induced NF-κB and AP-1-DNA binding 
and transcriptional activity was inhibited by mTOR overexpression whereas rapamycin 
was noted to enhance these OPN-induced effects. In the same study, OPN was shown to 
selectively phosphorylate p70S6 kinase at Thr-421/Ser-424 through MEK/ERK pathway 
but it did not phosphorylate p70S6 kinase at Thr-389 and Ser-371 sites which further 
suggested that mTOR inhibitor, rapamycin suppresses p70S6 kinase phosphorylation at 
Ser-371 and does not affect p70S6 kinase phosphorylation at Thr-421/Ser-424 and Thr-389 
sites indicating that Ser-371 phosphorylation is primarily responsible for p70S6 kinase 
activation in these cells (Figure 3).  
 
 
Fig. 3. Diagramatic representation of OPN-induced signaling cascades mediated by its cell 
surface receptor, integrin. These signaling pathways lead to upregulation of various 
oncogenic and angiogenic molecules that augment breast cancer cell migration, tumor 
growth, angiogenesis and inhibition of apoptosis, (Adapted from Chakraborty et al., 2008; 
Ahmed and Kundu, 2010; Behera et al., 2010 with modification). 
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7. Clinicopathological significance of osteopontin in breast cancer 
Effective management of breast cancer is possible by surgical removal of the tumor. Metastasis 
of tumor cells to secondary sites like bone, lung, liver and brain leads to poor survival. 
Although the detection system is not well established owing to the multifactorial nature and 
heterogeneity of cancer, early diagnosis can be made possible by identifying cancer 
biomarkers. Many earlier publications suggested that OPN may be considered as one of the 
potential candidate biomarkers in breast cancer. OPN is overexpressed in human breast cancer 
cells and tissues as well as in stromal compartment including CAFs. OPN plays a critical role 
in generation of calcification which is allied with breast cancer. Enhanced expression of OPN 
has been found in plasma and tumors of metastatic breast cancer suggesting that OPN may be 
considered as a prognostic marker (Bramwell et al, 2006). The plasma OPN level in women 
with known metastatic breast carcinoma is significantly higher than that of normal healthy 
individuals. The plasma OPN level in patients with metastatic breast cancer is higher than 138 
ng/ml versus control groups which have 123 ng/ml. Gene profiles compared between lobular 
versus ductal breast carcinomas using microarray analysis reveal 11 genes including OPN, and 
a specific change in gene expression (Korkola et al, 2003). An mRNA transcript analysis of 
OPN in normal, non-invasive, invasive and metastatic human breast cancer specimens shows 
that it’s level increases with enhanced malignancy. Moreover, a splice variant of OPN, namely 
OPN-C has been shown to be an important marker of breast cancer. It has been shown that 
OPN-C is selectively expressed in invasive, but not in non-invasive breast tumor cell lines. 
When the significance of OPN-C was studied in various tumor grades of breast cancer, the 
level of OPN-C increased from grade 1 to 3. Conclusively, these reports suggested that OPN-C 
is a selective marker of breast cancer (He et al, 2005). 
8. Therapeutic potential of OPN and its receptors 
Many OPN specific monoclonal and polyclonal antibodies have been generated. It has been 
observed that humanized anti-OPN antibody inhibits cell migration, adhesion, invasion, 
colony formation, tumor growth and lung metastasis in breast cancer (Dai et al, 2010). Thus 
for effective cancer management, targeting OPN by its specific blocking antibody may 
provide a novel therapeutic approach (Figure 4). The binding of OPN and its receptor 
controls the expression of various oncogenic molecules leading to tumor progression 
through various signalling pathways. Therefore, disruption of OPN and its receptor ligation 
may attenuate tumor growth and metastasis. v3 integrin blocking antibody inhibits OPN-
induced tumor growth and angiogenesis through attenuating various signaling cascades 
(Rangaswami et al, 2006). Decreased expression of OPN, integrin linked kinase (ILK), uPA 
and MMP-2 in murine mammary epithelial cancer cells was observed by blocking v3 
integrin (Mi et al, 2006). OPN can interact with various integrins and the specific blocking 
antibodies against these receptors can significantly suppress tumor-stromal interaction and 
reduce OPN-induced tumor progression (Figure 4). It has been recently documented that 
v3 integrin blocking antibody inhibits AP1 activation in response to OPN in breast cancer 
cells (Ahmed and Kundu, 2010). Inhibition of OPN and v3 integrin binding by LM609 
and RGD peptide attenuates STAT3 DNA-binding and suppresses cell migration and breast 
tumor growth by down regulating the expression of cyclinD1 and Bcl2 (Behera et al, 2010). 
Previous results have demonstrated that non-RGD-based integrin binding peptide (ATN-
161) suppresses breast tumor growth and metastasis (Khalili et al, 2006). 
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Fig. 4. Therapeutic targeting of OPN in breast cancer. The blocking antibody against OPN or 
its receptors such as integrin and CD44 impedes OPN regulated cancer signalling pathways 
leading to inhibition of breast tumor growth and angiogenesis through disruption of tumor-
endothelial cell interaction.  
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9. Conclusion 
Breast cancer accounts for major cancer related death in women around the world. 
Tremendous efforts are being made everyday in reducing the occurrence of breast cancer. 
Because of the complexity of the diseases, precise detection system is not available till date 
to diagnose the cancer at the early stages. Therefore, identification of novel biomarkers is the 
need of the hour. According to numerous publications, OPN may be considered as a 
potential biomarker in breast cancer because of its involvement in all the stages of tumor 
progression. Hence targeting OPN would be a rational approach for the treatment of cancer. 
In addition to tumor derived OPN, stromal OPN also plays a crucial role in regulation of 
tumor progression and angiogenesis. In conclusion, we have demonstrated that OPN 
regulates breast cancer cell migration through mTOR/p70S6 kinase dependent ICAM-1 
expression. Moreover, OPN also induces breast tumor growth and inhibits apoptosis 
through induction of JAK2/STAT3 dependent expression of Bcl2 and cyclin D1. 
Furthermore, OPN controls VEGF dependent breast cancer growth and angiogenesis 
through tumor-endothelial cell interaction via Brk/NIK dependent NF-B activation 
pathway. Thus in depth knowledge of OPN regulated signalling mechanism may be useful 
in developing novel molecular diagnostics and targeted therapy for the management of 
breast cancer.  
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